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Abstract
Background: We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and
Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) and updated this as Hereditary
angioedema: a current state-of-the-art review: Canadian Hungarian 2007 International Consensus Algorithm for the
Diagnosis, Therapy, and Management of Hereditary Angioedema.
Objective: To update the International Consensus Algorithm for the Diagnosis, Therapy and Management of
Hereditary Angioedema (circa 2010).
Methods: The Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d’angioédème héréditaire
(RCAH) http://www.haecanada.com and cosponsors University of Calgary and the Canadian Society of Allergy and
Clinical Immunology (with an unrestricted educational grant from CSL Behring) held our third Conference May
15th to 16th, 2010 in Toronto Canada to update our consensus approach. The Consensus document was reviewed
at the meeting and then circulated for review.
Results: This manuscript is the 2010 International Consensus Algorithm for the Diagnosis, Therapy and
Management of Hereditary Angioedema that resulted from that conference.
Conclusions: Consensus approach is only an interim guide to a complex disorder such as HAE and should be
replaced as soon as possible with large phase III and IV clinical trials, meta analyses, and using data base registry
validation of approaches including quality of life and cost benefit analyses, followed by large head-to-head clinical
trials and then evidence-based guidelines and standards for HAE disease management.
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Introduction
When our first consensus meeting took place in Tor-
onto, Canada in October 2003, there were no licensed
drugs in North America for the treatment of HAE
attacks and only two randomized clinical trials with
plasma-derived C1 inhibitor replacement therapy
(pdC1INH;[1,2]) and a few clinical trials using andro-
gens and antifibrinolytics [3-5]. C1-esterase inhibitor
concentrates (Berinert P® and Cetor®) were available
mostly in Europe at the time [Henkel G. CSL Behring -
Personal communication: Berinert approved for HAE
acute swelling therapy by Country and year of approval:
Argentina 2003; Australia January 2010; Austria 1990;
Belgium 2009; Bulgaria 2008; Canada 2010; Cyprus
2009; Czech Republic 2009; Denmark 2009; Finland
2009; France 2009; Germany - 1979 (predecessor pro-
duct, pasteurized product since 1985); Great Britain
2009; Greece 2009; Hungary 1997; Italy 2010; Japan
1990; Luxembourg 2010; Netherlands 2009; Norway
2009; Poland 2009; Portugal 2009; Romania 2009; Slova-
kia 2009; Slovenia 2009; Spain 2009; Sweden 2009; Swit-
zerland 1993; USA 2009]. There are now several phase
III clinical trials underway or reported in HAE therapy
and these have led to the licensing of pdC1INH in
many parts of the world including Europe and the Uni-
ted States, bradykinin receptor antagonist Icatibant in
Europe, and kallikrein inhibitor Ecallantide in the Uni-
ted States. More phase III clinical trials are currently
underway or pending reporting including pdC1INH
(Berinert®, CSL Behring; Cinryze®, ViroPharma; Cetor-
n®, Sanquin), recombinant C1-INH replacement therapy
(conestat alfa; Rhucin®, Pharming), kallikrein inhibitor
(Ecallantide, Kalbitor®, Dyax), and bradykinin-2-receptor
antagonist (Icatibant, Firazyr®, Jerini/Shire) (reviewed in
[6]). Consensus approaches require timely updating and
validation and hopefully with the establishment of data
base registries for HAE such as the European HAE Reg-
ister http://www.haeregister.org, the US Hereditary
Angioedema Association registry: http://www.hereditar-
yangioedema.com/, and the European Society for Immu-
nedeficiencies registry http://www.esid.org/esid_registry.
php such validation will occur including quality of life
(QOL) and cost benefit analyses and drug-drug compar-
isons. Consensus documents need replacing with evi-
dence-based recommendations based on large phase III
and IV trials, head-to-head drug comparisons, meta ana-
lyses, guidelines and then standards and we look for-
ward to the improved care of HAE patients as these roll
out. To update our previous consensus approach, the
Canadian Hereditary Angioedema Network (CHAEN)/
Réseau Canadien d’angioédème héréditaire (RCAH)
http://www.haecanada.com and cosponsors University of
Calgary and the Canadian Society of Allergy and Clinical
Immunology (with an unrestricted educational grant
from CSL Behring) held our third Consensus Confer-
ence May 15th to 16th, 2010 in Toronto Canada. This
manuscript is the 2010 International Consensus Algo-
rithm for the Diagnosis, Therapy and Management of
Hereditary Angioedema that was agreed to at that con-
ference and this was further circulated for review and
comment to previous consensus participants. Speakers
at the Conference were encouraged to submit their
views for publication and these manuscripts are pub-
lished together as a thematic publication grouping on
HAE in the official journal of the Canadian Society of
Allergy and Clinical Immunology: Allergy Asthma Clini-
cal Immunology; 2010 (in press [6-16]).
Patient Group Perspective
Similar to the six Hungarian-sponsored HAE Work-
shops as indicated in their publication [17], it is appro-
priate that Patient Groups participate in HAE
management consensus discussions to share the patient
perspective of HAE management and to help reflect on
the development of comprehensive care clinics, home
therapy programs, and overall management of HAE.
The Canadian and Canadian Hungarian consensus
document processes [18,19] included Patient Group par-
ticipation in discussion, approval, and co-authoring.
Patient groups should participate in and coauthor con-
sensus treatment documents affecting their care. The
Patient Advisory Committee of the Canadian Hereditary
Angioedema Network (CHAEN)/Réseau Canadien d’an-
gioédème héréditaire (RCAH) http://www.haecanada.
com and HAE - International Patient Organization for
C1 Inhibitor Deficiencies (HAEi) http://www.haei.org
participated in the Conference.
HAE Diagnosis Algorithm: See Figure 1
Clinical Characteristics
Clinical characteristics are reviewed in previous docu-
ments [1,6-20]. Patients with HAE may experience
recurrent nonpruritic edema of skin and submucosal tis-
sues associated with pain syndromes, nausea, vomiting,
diarrhea, and life-threatening airway swellings. Risk of
dying from airway obstruction if left untreated is signifi-
cant [9,17,21]. A prodromal serpiginous erythematous
rash is sometimes seen but pruritic urticaria usually
makes the diagnosis of HAE unlikely [17,20,22]. HAE
genetics are autosomal dominant with 25% spontaneous
mutation; the HAE-C1INH gene mapping to chromo-
some 11q12-q13.1 [17-19]; and the protein defect
described by Donaldson in 1963 [23]. An acquired form
(acquired angioedema, AAE) was described in 1972
(reviewed in [10]) and is not the focus of this article.
AAE differs from HAE having absent family history, late
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onset of symptoms, usually low C1q antigen levels, pro-
phylactic response to antifibrinolytics often better than
to androgens, and sometimes requiring markedly higher
doses of pdC1INH with rapid C1-INH catabolism and
may respond to Icatibant or Ecallantide [10,24]. Drug-
induced angioedema (e.g. angiotensin-converting
enzyme inhibitors, ACE-I) is also not included in this
discussion [22]. The incidence of HAE is approximately
1:50,000 with no ethnic group differences [17,19]. There
seems to be little or no genotype phenotype correlation
Figure 1 Hereditary Angioedema - HAE - Diagnostic Algorithm.
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[17]. Two forms of HAE have been described: type I
HAE with low C1-INH antigenic protein and functional
activity (85% of cases) and type II HAE with normal or
elevated protein but low C1-INH function (15% of
cases); and HAE with normal C1-INH often referred to
as type III HAE. HAE with normal C1-INH occurs
mainly in women and includes HAE associated with
mutations in the coagulation factor XII gene and other
defects yet to be identified [11,13,18,19,25]. The patho-
physiology of types I and II HAE has been elucidated
with the candidate molecule resulting in angioedema
being bradykinin [17,18,23,25-28]. Age of onset is vari-
able and may present under one year of age
[1,6,7,18,19,25] with laryngeal attacks uncommon before
age three and tend to occur later than other symptoms
[8,18-20,29-31]. Angioedema events often worsen with
puberty, estrogen-containing birth control pills, or hor-
mone replacement therapy [8,11,13,15,17,19,20,31,32].
Untreated attacks typically last over 48 to 96 hours
[17,20]. Attack triggers may include stress, infections,
ACE-inhibitors, minor trauma, menstruation, pregnancy,
oral contraceptives but are often unidentified with
attacks varying from periodic, clustering, periods of
remission [17-20,26,29,31]. Angioedema attacks do not
respond to treatment with glucocorticoids or antihista-
mines, and epinephrine has only a transient and modest
benefit [18,19,26,33].
Diagnostic Algorithm: See Figure 1
Indications for testing include clinical suspicion or posi-
tive family history [8,19,20,22,29-31]. Testing under one
year of age may not be reliable and should be confirmed
after age one (false negative and false positive tests may
occur unless using genetic typing) [8,19,20,29-31]. If
clinical suspicion of C1-INH deficiency, we recommend
screening with C4, (C4 is normal between swelling
events in only 2% of cases; [19,31]), C1 inhibitor anti-
genic protein and C1 inhibitor function, if available.
However, a normal C4 particularly during an edema
attack should make one question the diagnosis of
HAE (there is no indication for screening CH50 nor
C3) [6,8,10,19,22,29,31]. If serum C4 and C1-INH anti-
genic proteins are both low (below manufacturer’s nor-
mal range) and AAE not suspected, then the diagnosis
is compatible with HAE-C1INH-Type I (Type I HAE)
(suggest repeat testing once to confirm). If AAE is possi-
ble such as with no family history and later onset of
symptoms (age over 40), then serum C1q antigenic pro-
tein testing is suggested. If low C1q, the diagnosis is
compatible with AAE (C1q antigenic protein is reduced
in 75% of AAE but usually normal in HAE; [10]). If C4
is normal or low and C1-INH antigenic protein normal
but clinical suspicion is strong, HAE is NOT ruled out
and C1-INH functional assay should be obtained (in a
laboratory skilled in functional C1-INH assay with care-
ful sample drawing, handling, shipping, and interpreting
results) [8,18,19,28,29,34]. If C1-INH functional activity
is low with normal or elevated C1-INH antigenic pro-
tein and normal C1q, this is compatible with HAE-
C1INH-Type II (Type II HAE) (tests should be
repeated at least once to confirm the diagnosis; sample
mishandling is common) [8,18,19,28,29,34]. If C4 anti-
genic protein and C1-INH functional assays are both
normal, this rules out Types I and II HAE but does not
rule out type III HAE (HAE-FXII and HAE-
Unknown) (normal C1-INH protein and function
occurring mainly in women; some with mutations in the
coagulation factor XII gene or other unidentified defects;
[11,13,19,25,35] nor medication-related angioedema
(e.g. ACE-I-related Angioedema; [10,19,22]). If C4 and
C1-INH protein are normal, we suggest repeating these
during an acute attack [19,28]. Genetic testing is usually
not necessary to confirm the diagnosis of HAE-C1INH
types I and II particularly if positive family history (auto-
somal dominant with approximately 25% representing
de novo mutations) [8,19,29,31]. However, genetic test-
ing is occasionally helpful in confirming HAE-C1INH
(particularly before one year of age and cord blood; [8])
and may contribute to investigation of type III HAE
[8,11,13,19,25]. Although C4 and C1-INH protein anti-
gen are routine laboratory tests, C1-INH functional
assays are specialized laboratory tests and should
only be done in reference laboratories with careful
attention to sample handling for complement
[8,11,13,17,19,28,29,34]. C1-INH functional assays may
use chromogenic or C1s binding ELISA assays. Both dis-
tinguish between normal and abnormal but the C1s
ELISA assay performance may be poor if manufacturer’s
normal range (> 67%) is used. The reference laboratory
should determine normal range locally with receiver
operator characteristic (ROC) analysis, since higher cut-
off (84%) may give better discrimination [34].
Baseline laboratory testing at diagnosis at any
age and follow up
Baseline blood borne pathogen surveillance (hemovigi-
lance) samples should be collected and stored at base-
line and annually including testing for hepatitis B, C, G;
HIV; HTLV; parvovirus and future testing for possible
emerging pathogens (serum and nucleic acid storage
[19,29,31]. As pdC1INH may be required at any time on
an emergency basis after diagnosis, hemovigilance and
baseline chemistries and urinalysis are best done at diag-
nosis. Although production methods for pdC1INH may
differ, safety of new generation pdC1INH has been
excellent [19,28,29,31,36-38]. Since attenuated andro-
gens may predispose to lipid abnormalities [39] and
liver disorders including liver cancer, we suggest
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[1,7,11,12,17,19,37] serum lipid profile and liver function
tests be obtained prior to androgen administration and
abdominal liver and spleen ultrasound be performed
prior to continuous androgen administration (repeated
annually) [8,17,19,28,29,31,40]. Liver function studies
(including alanine aminotransferase, ALT, total bilirubin,
alkaline phosphatase, albumin, alk phos, and possibly
PT/PTT and alpha fetoprotein); creatine kinase (CK),
lactic dehydrogenase (LDH), blood urea nitrogen (BUN),
creatinine (Cr), complete blood count (CBC) and differ-
ential; as well, urinalysis should be obtained at diagnosis
[8,17,19,28,29,31,40,41].
Vaccination recommendations
We recommend that patients at risk for receiving blood
products receive vaccination to hepatitis B (may be
combination hepatitis A) [8,19,29,31].
Medications to avoid in patients with HAE
Some medications may trigger or worsen angioedema
events in patients with HAE and should be avoided
including estrogen contraceptives, hormone replacement
therapy, and ACE-Inhibitors [8,11,13,17,19,22,29,31,32].
Plasminogen activators are a theoretical risk but the
benefit may outweigh the risk [19].
Short-Term Prophylaxis - see Figure 2
Minor Manipulation - such as mild dental work
(injection of local anaesthetic may precipitate an
attack): if pdC1INH is immediately available, then no
prophylaxis (unless such manipulations have previously
precipitated an attack in that patient in which case
prophylaxis with pdC1INH should be considered). If
pdC1INH is not available, then 17-alpha-alkylated ana-
bolic androgen (Danazol most widely used but also sta-
nozolol and oxandralone) or antifibrinolytic
prophylaxis (if available, tranexamic acid is preferred
to epsilon aminocaproic acid) (see Figure 2). Tranexa-
mic acid as a 5% mouthwash may decrease bleeding
from dental procedures and may prevent bradykinin
formation in plasminogen rich saliva [42-44]. If consid-
ering more than mild manipulation, pdC1INH prophy-
laxis should be considered. If pdC1INH not available,
then short term Danazol is recommended (even in
children and last trimester of pregnancy - avoid in the
first two trimesters of pregnancy; [8,15,19,29,31,32].
The recommended dose is 2.5 to 10 mg/kg/day, maxi-
mum 600 mg daily, for five days before and two to five
days after the event [8,19,29,31]; Stanozolol 4-6 mg/
day is an alternative [29]. Whenever possible,
PdC1INH should be immediately available
[8,19,29,31]. Since anabolic androgens such as Danazol
are more efficacious in the short term compared to
antifibrinolytics such as Tranexamic acid (TA;
Cyklokapron®) or epsilon aminocaproic acid (EACA;
Amicar®), anabolic steroids are more often used for
short term prophylaxis in the setting where pdC1INH
is not available [8,19,29,31]. The recommended dose
for oral TA (not fully established) is 25 mg/kg two to
three times daily with maximum 3 to 6 g daily; IV
dose 10 mg/kg two to three times daily adjusting the
dose for renal impairment [19,29,31,33,45-48].
Intubation or major procedures - pdC1INH one
hour pre surgery - as close to procedure as feasible -
less than six hours before the procedure (should always
be given if endotracheal intubation or manipulation;
[8,9,12,14,19,29,31,45]. The optimal dose for prophylaxis
for procedures has not yet been established - we recom-
mend 10 to 20 units per kg [8,9,12,14,19,29,31,45]. A
second dose of equal amount should be immediately
available at time of surgery. Repeat daily as needed until
there is no further risk of angioedema. If pdC1INH is
not available, then Danazol or Stanozolol are recom-
mended as in V.1 (see figure 2; androgens preferred to
TA; TA in doses as above; [19,29,31,33,45,47].) Solvent/
detergent treated plasma (SDP; 10 ml/kg; 2 to 4 units,
400 to 800 ml per adult infusion) is an option one to six
hours presurgery (fresh frozen plasma or frozen plasma
is less safe than SDP; [8,9,19,28,29,31,33,48]; Dr. Mike
Frank’s group has reported using two units fresh frozen
plasma the night before, [49-51]).
Pregnancy
pdC1INH prophylaxis is the safest prophylactic agent
during pregnancy [12,15,19,29,31,32]; discussed at the
6th International HAE Conference held in Budapest in
June 2009; dose as in V.2).
Pediatrics
except when undergoing surgical or diagnostic interven-
tions in the head and neck region, short-term prophy-
laxis is less often required in children than adults
(dosing as in V.1 and V.2; [8,31]).
Long-Term Prophylaxis: See Figure 2
Prophylaxis indications have been reviewed
[12,17,19,52]. Consider prophylaxis with antifibrinolytics,
attenuated androgens, or pdC1INH if more than one
severe event per month occurs and if a treatment for
acute attacks is not sufficiently effective or is not avail-
able [8,12,19,28,37,52-54]. It should be noted that: the
number of events per year does not predict severity
of the next event nor whether the first or next event
will be an airway event.
17-alpha-alkylated anabolic androgens
Attenuated androgens such as Danazol and Stanozolol
are the usual agents with methyltestosterone and
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oxandrolone as alternatives. Androgens are generally
more effective than antifibrinolytic agents [8,17-19,40].
Androgen contraindications usually include pregnancy,
lactation, cancer, hepatitis, and childhood (until finished
growing) [8,15,17-19,29,31,32]. Side effects may include
virilization, weight gain, acne, hair growth, altered libido,
voice deepening, decreased breast size, menstrual irregu-
larities, vasomotor symptoms, hypertension, atherogen-
esis, altered lipid metabolism, altered liver enzymes,
cholestasis, hepatic necrosis, liver neoplasms (hepatocel-
lular adenomas or carcinomas), erythrocytosis, hemor-
rhagic cystitis, and ambiguous genitalia in newborns if
mothers treated with androgens during pregnancy
[8,17,19,28,37,40,41,55,56]. Androgen induction can be
with high dose and reduce or low dose and escalate
aiming to achieve the lowest effective dose (maximum
long term doses recommended are 200 mg daily for
Danazol and 2 mg daily for Stanozolol) [17-19,28,29,31,
35,37,40,55]. Androgen therapy is not recommended for
children but has been used in the prepubertal setting
[8,17,19,29,31,35]. If patients are exposed to a precipitat-
ing factor such as infection or if the sensation of pro-
dromal attack symptoms or mild clinical manifestations
developing, then doubling the dose for several days has
been tried. The lowest effective maintenance dose
including trying alternate day or twice weekly should be
tried [19,28,29]. Danazol has been used in children
[8,31,35] but pdC1INH may be the safest long term
Figure 2 Hereditary Angioedema - HAE - Prophylaxis Algorithm.
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approach [8,31,35]. Danazol has been used for prophylaxis in
HAE type III as have progesterone and tranexamic acid [11].
Androgen Monitoring
every six months: liver enzymes (ALT, AST, alk phos),
lipid profile, complete blood cell count, and urinalysis.
For adults with a dose of 200 mg or less per day Dana-
zol: suggest an annual liver spleen ultrasound. In prepu-
bertal patients or in adults with doses higher than 200
mg Danazol daily: suggest six monthly liver spleen ultra-
sound for the detection of focal lesions and annual alpha
fetoprotein [8,19,29,31,35,57-60].
Antifibrinolytic Agents (AFs;[45])
Tranexamic acid (TA; Cyklokapron®) is more effective
than epsilon aminocaproic acid (EACA; Amicar®;[3])
and has mostly replaced EACA outside the USA. AFs
may not be as effective as androgen therapy in HAE but
may be useful in AAE [10,17,19,28]. TA is mostly used
for prophylaxis in children before Tanner V puberty
stage or if not wanting to risk androgen prophylaxis
[8,17,19,29,31,35]. Dyspepsia is common and can be
reduced by taking the drug with food. Other side effects
may include myalgia, muscle weakness, elevated serum
creatine phosphokinase or aldolase, rhabdomyolysis
(EACA particularly), hypotension, fatigue, and retinal
changes (seen in animals) [19,35,44,45]. TA dosage is
not well established [4,8,17,19,29,31,35,45] aiming for
the lowest effective maintenance with recommended
starting dose of 20 to 50 mg/kg/day (split 2 to 3 times
daily, taken with food, with daily maximum of 4 to 6 g;
[4,8,17,19,35,44,45]. The dose may be able to be reduced
to 0.5 g once or twice daily or even alternate-day or
twice weekly regimens [29]. TA Monitoring: six
monthly CK, urinalysis, liver and renal function; annual
ophthalmology check for eye pressure (risk of glaucoma)
[8,19,29,31,35]. AFs have not been associated with
excess thrombosis or myocardial infarction in controlled
trials [61-64], but there are case reports of thrombosis
in patients with hypercoagulable states treated with AFs
[65,66], so it is prudent to use it cautiously if there is a
family history of thrombophilia or active thromboem-
bolic disease [35,45,65,66]. TA was reported effective
long-term prophylaxis in HAE type III [67].
Plasma-derived C1 inhibitor - pdC1INH
Home pdC1INH self-infusion programs should be
offered to patients (created similar to hemophilia self-
infusion programs which have existed for 35 years;
[8,12,17,19,29,31,36,37,52,68,69]. The dose including
dose per kg for prophylaxis has not been fully estab-
lished [12,14,36,37,70]. We recommend 500 units (if less
than 50 kg, 110 lb) or 1000 units (if greater than 50 kg,
110 lb) [1,12,14,19].
Cinryze® from ViroPharma is FDA approved for ado-
lescent and adult prophylaxis at a dose of 1000 units
every three or four days (see FDA approved package
insert:
http://www.fda.gov/BiologicsBloodVaccines/Blood-
BloodProducts/ApprovedProducts/LicensedProducts-
BLAs/FractionatedPlasmaProducts/ucm150480.htm)[12].
Prophylaxis with pdC1INH is not 100% effective http://
www.cinryze.com/documents/cinryze-prescribing-infor-
mation.pdf. Cetor® from Sanquin is licensed in the
Netherlands http://www.sanquinreagents.com/sanquin-
eng/sqn_products_plasma.nsf/8551110e498bd2c8c1
2572110034decf/11343072be4286d2c125702a004a4e50/
$FILE/Cetor%20SPC.pdf.
Berinert® from CSL Behring is approved for therapy
in many countries around the world including Europe
and by USA FDA (see FDA approved package insert:
http://www.fda.gov/BiologicsBloodVaccines/Blood-
BloodProducts/ApprovedProducts/LicensedProducts-
BLAs/FractionatedPlasmaProducts/ucm186264.htm).
Reconstitution and administration of PdC1INH as per
package inserts (see above web links; [18,19,35]). DO
NOT SHAKE as this will denature the protein. Admin-
istration should be via peripheral vein (usually over ten
minutes) (see product package insert references above
for administration details) [8,18,19,29,31,35].
Treatment of Acute HAE Attacks - see Figure 3
We recommend treating attacks as early as possible.
Plasma-derived C1-INH - PdC1INH
PdC1INH has been the first line therapy for several dec-
ades in Europe and elsewhere and used for many years
in Canada under Special Access Program
[8,12,17-19,29,31,35,37,38,48,52-54]. Berinert® from CSL
Behring was licensed by USA FDA October 9th, 2009
for therapy of HAE events and licensed in many other
countries for many years. Cetor® from Sanquin has been
available in The Netherlands for some time [35,53]. Ber-
inert®, CSL Behring, has been shown to be more effec-
tive than placebo for therapy of acute angioedema
attacks at a dose of 20 units/kg (see package insert
reference above; [12,35,71]). However, use in other
countries is 500 to 1500 units [8,14,19,29,31,37,53,
54,72]; Cetor dose recommendation is 1000 units -
http://www.sanquin.nl/sanquin-eng/sqn_products_-
plasma.nsf/8551110e498bd2c8c12572110034decf/
11343072be4286d2c125702a004a4e50/$FILE/Cetor%
20SPC.pdf). PdC1INH has been well tolerated and viral
transmission attributed to new generation pdC1INH has
not been reported [33,36-38,73]. As pdC1INH is a blood
product, annual recipient hemovigilance and vein-to-
vein tracking are essential (tracking and hemovigilance
similar to home therapy programs for Hemophilia Com-
prehensive Clinics). PdC1INH has been used to treat
HAE attacks in HAE Type III [11,67].
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Icatibant
Icatibant (Firazyr® from Jerini/Shire) is a small peptide,
bradykinin receptor blocker approved for use in treat-
ment of HAE in the European Union. Dose is 30 mg
subcutaneously in adults. Pediatric experience is pend-
ing. Although not usually needed, the dose can be
repeated six hourly twice more if needed (see package
insert for Firazyr®). Local reactions are common with
injection [6,28]. Icatibant may be beneficial in type III
HAE [11,74].
Ecallantide
Ecallantide, DX-88, Dyax, Kalbitor® is a small peptide,
kallikrein inhibitor approved for treatment of HAE in
the USA since December 2009. Dose is 30 mg subcuta-
neously (adults). It is not recommended for self infusion
at this time because of a small risk of anaphylaxis and is
being further studied in phase IV clinical trial [6].
Emerging Therapies
Recombinant C1-INH, conestat alfa, Rhucin® is recom-
binant human C1-INH produced in transgenic rabbit
milk [6,28]. Currently under FDA review, in June 2010
it received a positive opinion from the European Medi-
cines Agency’s (EMA) Committee for Medicinal
Products for Human Use (CHMP) for the treatment of
acute angioedema attacks in patients with HAE. With
this positive opinion, the CHMP recommends the Eur-
opean Commission to grant the European Marketing
Authorization. The product will be marketed in the EU
under the name Ruconest®.
As new therapies become available, it will be very
important to conduct rigorous phase IV clinical trials
(utilizing data base registries such as HAEA and HAEI
and ESID provide) so that long term safety efficacy data
on these therapies can be closely monitored and to
allow comparison of cost benefit studies including qual-
ity of life issues between the various therapies. This will
provide funding organizations and patients better infor-
mation on which to base their choices of products pro-
vided under pharmaceutical plans and the most cost
effective product for patient choice. It is exciting to
finally have licensed therapeutic and prophylactic medi-
cations for treatment of this disorder.
Other treatments
If the above currently available therapies such as
pdC1INH, Icatibant, and Ecallantide are not available,
other therapies may include increasing (usually dou-
bling) the androgen (Danazol or Stanozolol) dose or
antifibrinolytics [8,17,19,29,31,35]. However, unlike
Figure 3 Treatment of Acute Hereditary Angioedema - HAE - Attacks.
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pdC1INH, Icatibant, and Ecallantide, there are limited
data to support this recommendation [3-5]. Use of sol-
vent detergent plasma (SDP; preferred for viral trans-
mission reasons over FP/FFP) could theoretically worsen
attacks and remains controversial and again there are no
clinical trials to support its use [8,19,29,31,35]. Adrena-
line has been used but is usually of only modest and
transient benefit [8,19,29,31,75]. Pain management,
intravenous fluids, and supportive care are essential but
do not affect the outcome of an attack and therefore are
not a replacement for early intervention with pdC1INH,
Icatibant, Ecallantide or possibly recombinant C1INH or
other emerging therapies.
Comprehensive Care Clinics - Home Therapy: see
Appendix 1
Comprehensive care clinics for immunedeficiencies, rare
blood disorders, hemophilia, cystic fibrosis, asthma, can-
cers and many other disorders have improved survival
[76,77] and contributed to improved standard of care
for these disorders (see proceedings of the Canadian
National Rare Blood Disorders meeting:
http://www.hemophilia.ca/en/about-the-chs/collabora-
tion/network-of-rare-blood-disorder-organizations/2009-
progress-in-comprehensive-care-for-rare-blood-disor-
ders-conference——presented-by-csl-behring/#c969).
Comprehensive care for HAE is based on the recogni-
tion that HAE is a chronic disease and care is complex,
requiring a highly specialized and multidisciplinary
approach. A comprehensive care clinic must provide
accountability for in-hospital and home use of expensive
and potentially toxic treatments, track outcomes (both
beneficial and adverse), and develop and meet Standards
of Care for HAE. It is recommended that HAE patients
be linked with comprehensive care clinic programs
(bringing together clinical care, education and research)
to facilitate diagnosis, therapy, management; facilitate
data base registries; allow rigorous safety efficacy
monitoring of emerging therapies of HAE; and to facili-
tate access to home therapy programs (similar to
the model for comprehensive care of hemophilia)
(see blood disorder conference link above;
[8,16,19,29,31,36,35,37,54,68]). One clinic model can be
found in Appendix 1 (also see [19,29,31]). Patients are
encouraged to carry “alert” identification (wallet card
example may be found at: http://www.haecanada.com/
files/WalletCard_Bilingual.pdf) and an accompanying
letter indicating the diagnosis of HAE (with type), mate-
rials necessary to be carried for care for presentation at
air line and other security areas, and outlining instruc-
tions for administration of intervention therapy (such as
infusion of pdC1INH). It is recommended that HAE
organization websites provide infusion instructions for
downloading by patients and comprehensive care clinics
(example of home infusion technique may be viewed at:
http://haecanada.com/infusion/index.html) Home ther-
apy and particularly home pdC1INH infusion programs
should be offered to patients. Such programs should be
created similar to hemophilia home infusion programs
which have existed for 35 years (see blood disorders link
above; [8,14,16,17,19,29,31,35-37,52,54,68]). Home care
was discussed at the 6th International HAE Conference
held in Budapest in June 2009 http://www.haenet.hu/
new/program_C1INH2009.pdf and the resulting home
care consensus approach has been assembled [16].
Pediatrics
Most of the pediatric considerations of HAE are incor-
porated in the above algorithms (Figures 1, 2 and 3 and
Appendix 1) and have been reviewed elsewhere. Most
treatment drugs have been licensed for adults with
pediatric licensing pending [6,8,14,18,19,29-31,35].
Pregnancy and Lactation
Most of the pregnancy and lactation considerations of
HAE are incorporated in the above algorithms (Figures
1, 2 and 3 and Appendix 1) and have been reviewed
elsewhere. Most treatment drugs have not been trialed
in pregnancy and are not licensed for use in this setting
although there is anecdotal use of pdC1INH use in
pregnancy and lactation [6,15,19,29,32,33,52,53]. Tra-
nexamic acid can be found in breast milk [44].
Conclusion
Since our first Canadian International Consensus meet-
ing in 2003 when plasma-derived C1-inhibitor concen-
trates had been available for decades in Europe but not
widely outside Europe, many new therapies have
emerged in HAE management. Many phase III clinical
trials have been completed and some reported on. Sev-
eral products are now licensed for prophylaxis and ther-
apy of HAE and hopefully are reducing the morbidity
and mortality in this disorder. These therapies and
home care concepts are providing freedom for work,
travel, and every day activities including sports activities
with more normalization of life style and improved qual-
ity of life for HAE patients. We must strive to elevate
the standard of care for HAE patients through compre-
hensive care clinics and home care programs and insti-
tute safety, efficacy, and cost benefit monitoring. Data
base registries may provide the health care systems,
patients, and patient groups with the necessary data to
choose the most appropriate individualized management
of one’s HAE. Consensus approaches are only interim
guides to chronic and rare diseases such as HAE and
should be replaced as soon as possible with more phase
III studies, meta analyses, large phase IV post-marketing
trials, and head-to-head studies using data base registry
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validation of consensus approaches including quality of
life and cost-benefit analyses followed by guidelines and
then standards for HAE disease management.
Appendix 1 - Comprehensive Care Clinics for
Hereditary Angioedema - 2010 05 27
(Modified by permission from: http://www.haecanada.
com - comprehensive care clinics)
Comprehensive Patient Care Clinics: Clinical care,
Education, and Research
Comprehensive care for HAE is based on the recogni-
tion that HAE is a chronic disease and care is complex,
requiring a highly specialized and multidisciplinary
approach. A comprehensive care clinic must provide
accountability for in-hospital and home use of expensive
and potentially toxic treatments, track outcomes (both
beneficial and adverse), and develop and meet Standards
of Care for HAE.
Comprehensive HAE Clinics will Provide
1 Best Clinical Treatment outcomes including:
a. a comprehensive care team made up of nurse
coordinator, clinician, social worker, data man-
ager, pain management specialist, genetic coun-
sellor, and administrative support;
b. access to specialized diagnostic testing;
c. access to home treatment;
d. a networked Patient Information System to
facilitate product recalls - collect data on therapy
outcome measures and safety, and facilitate parti-
cipation in clinical trials
e. access to clinical advances as they become
available;
f. access to 24 hour support;
g. access to up-to-date standards of care, includ-
ing standardized wallet cards;
h. tracking and intermittent audit of quality out-
comes including beneficial and adverse outcomes
through secure, comprehensive and networked
data management.
2 Education of patients and staff regarding:
a. responsible Self/Family Care (home care
model) with home and self infusion/administra-
tion instruction and support;
b. developments in the cause, diagnosis, treat-
ment, outcomes, and prognosis of HAE
c. changes in the administrative management of
the clinic
3 An environment conducive to research including:
a. access to and support for clinical trials of new
treatments;
b. access to and support for translational
research in diagnosis and prognosis;
c. accesss to and support for psychosocial
research such as quality of life studies.
4 An advisory or oversight board with patient group
representation for each clinic
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